Dr. Yan-Yan Jiang completed her B.S. and M.S. study in pharmaceutics from Shenyang Pharmaceutical University and obtained Ph.D. degree from Fudan University. She took her current position of Associate Professor at Fudan University in 2007. Dr. Jiang’s research interests are focused on exploring novel strategies of tumor therapy, as well as new dosage form and preparations, including using intelligent polymer materials, micro/nano particles and cells as drug carriers. Her research projects are supported by National Natural Science Foundation of China, the foundation of Shanghai Commission of Science and several company foundations. As first author or corresponding author, the research achievements were published in Advanced Materials, Biomaterials, Pharmaceutical Research, European Journal of Pharmaceutics and Biopharmaceutics and so on. So far she hold 3 patents. She is reviewer of several international journals.
Targeted drug delivery systems; Bionic carriers; nanomedicines; New dosage forms of drugs
Education
1986.9 ~ 1990.6 Shenyang Pharmaceutical University, School of Pharmacy. Pharmaceutics, Bachelor.
1995.9 ~ 1999.6 Shenyang Pharmaceutical University, School of Pharmacy. Pharmaceutics, Master.
2001.9 ~ 2005.6 Fudan University, School of Pharmacy. Pharmaceutics, Ph.D.
Professional Experiences
1990.7-1992.5 Kunming Yanan Hospital, Pharmacy dispensary, Pharmacist
1992.5-1995.6 Harbin Fifth Hospital, Pharmacy dispensary, Pharmacist
1999.7-Present Fudan University, School of Pharmacy, Associate Professor
Teaching Activities
Conduct 2 specialized course for undergraduate students, namely a required course "Pharmaceutics I" and an elective course "Biotech Drug Delivery System ". Co-teaching for 2 specialized course of undergraduate students, namely a required course "Introduction to Pharmaceutics" and an elective course "Polymers for Pharmaceutical Application". Co-teaching for 2 postgraduate course, namely "Targeted Drug Delivery Systems" and "Selected Topics of Advanced Pharmaceutics".
Grants & Projects
Conducting 4 government-aided projects, of which 3 was funded by The National Natural Science Fund of China (NSFC) and one was funded by Science and Technology Commission of Shanghai Municipality (STCSM), and participating in 5 research projects supported by NSFC and STCSM. In addition, 8 cooperate program with enterprises have been completed.
Awards & Honors
Shanghai Excellent Course, Second Award. Awarded by Shanghai Municipal Commission of education.
4th《Acta Pharmaceutica Sinica》Excellent Research Paper.
Excellent Teaching Achievements Award of Fudan University.
Science and Technology Award of Chinese Pharmaceutical Association, Third award.
Selected Publications（latest 5 yrs，<20 papers）
1. Sen Yao, Xuqian Li, Jingxuan Liu, Yuqing Sun, Zhuanhe Wang & Yanyan Jiang*. Maximized nanodrug-loaded mesenchymal stem cells by a dual drug-loaded mode for the systemic treatment of metastatic lung cancer. Drug Delivery, 2017,24(1): 1372–1383.
2. Liu Chang, Yao Sen, Li Xuqian, Wang Feng, *Jiang Yanyan. iRGD-mediated core-shell nanoparticles loading carmustine and O6-benzylguanine for glioma therapy. J Drug Target, 2017, 25(3): 235-246.
3. XF Zhang, S Yao, C Liu, YY Jiang*. Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy. Biomaterials, 2015, 39: 269-281.
4. K Wang, XF Zhang, Y Liu,C Liu, BH Jiang*, YY Jiang*. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials, 2014, 35:8735-8747.
5. K Wang, XF Zhang, LH Zhang, LL Qian, C Liu, JJ Zheng, YY Jiang*. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release. Drug Deliv, 2015, 22(3): 389–399.
6. LL Qian, JJ Zheng, K Wang, Y Tang, XF Zhang , HS Zhang, FP Huang*, YY Pei, YY Jiang*. Cationic core-shell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy. Biomaterials, 2013, 34: 8968-8978.
7. QI Wen, SHI Bin, HUANG Xiong-wei, XI Zhi-jun, JIANG Yan-yan*, PEI Yuan-ying. In vitro characteristic evaluation of ursolic acid co-crystal solid dispersions. Chinese Traditional and Herbal Drugs, 2013, 44(20): 2845-2851.
8. QI Wen, CHEN Ming, JIANG Yan-yan*, PEI Yuan-ying. Study on the preparation and in vitro evaluation of ursolic acid solid dispersions. Chin Hosp Pharm J, 2013, 33(2): 108-111.
9. Tang Guotao, Zhu Saijie, Hong Minghuang, Jiang Yanyan*, Pei Yuanying. Study on tumor active targeting with Transferrin-PEG-PAMAM dendrimer-CPT conjugate. Anti-tumor Pharmacy, 2012, 2(2): 93-100.
10. SJ Zhu, LL Qian, MH Hong, LH Zhang, YY Pei, YY Jiang*. RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular cells and tumor cells. Advanced Materials, 2011, 23: H84–H89.
11. Lihong Zhang, Saijie Zhu, Lili Qian, Yuanying Pei, Yongming Qiu*, Yanyan Jiang*. RGD-modified PEG-PAMAM-DOX Conjugates : In vitro and In vivo Studies for Glioma. Eur. J. Pharm. Biopharm, 2011, 79: 232-240.
12. SJ Zhu, MH Hong, GT Tang, LL Qian, JY Lin, YY Jiang*, YY Pei. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials, 2010, 31:1360-1371.
13. SJ Zhu, MH Hong, LH Zhang, GT Tang, YY Jiang*, YY Pei. PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: In vitro Evaluation, and In vivo Tumor Accumulation. Pharmaceutical Research, 2010, 27: 161-174.
Patents
Applied for 5 patents as patent holder and 3 of them have been authorized by State Intellectual Property Office of China (SIPO) as followed.
1. Jiang Yanyan, Qian Lili, Wang Feng, et al. A kind of RGD peptide modified double-drug-loaded nanoparticles and preparation method. ZL201110441211.5, April 22nd, 2015
2. Jiang Yanyan, Zhu Saijie, Pei Yuanying, et al. A dendrimer-drug antitumor nano-prodrug system and preparation method China. ZL200910050946.8, February 1st, 2012
3. Jiang Yanyan, Pei Yuanying, Liu chen, et al. Transferrin-PEG-drug conjugates and its application. ZL200610028503.5, March 12th, 2010
